.jpg "LivaNova PLC (NASDAQ: LIVN)")
In a report issued on November 19, Sean Lavin from BTIG maintained a Hold rating on LivaNova PLC (LIVN). The company’s shares closed yesterday at $98.04.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 8.4% and a 54.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for LivaNova PLC with a $142.60 average price target.
See today’s analyst top recommended stocks >>
Based on LivaNova PLC’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.18 million. In comparison, last year the company had a net profit of $27.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the Cardiac Surgery and Neuromodulation, and Other Corporate segments.
